1. Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics
- Author
-
David Altarac, Manos Perros, Matthew Ronsheim, Tommasi Ruben A, John P. Mueller, and Michael Gutch
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Biomedical Research ,medicine.drug_class ,Antibiotics ,Commercialization ,Antimicrobial Stewardship ,03 medical and health sciences ,Technology Transfer ,0302 clinical medicine ,Antibiotic resistance ,Drug Development ,Drug Discovery ,medicine ,Animals ,Humans ,Antimicrobial stewardship ,Intensive care medicine ,Pathogen ,Reimbursement ,Pharmacology ,Bacteria ,business.industry ,Bacterial Infections ,Anti-Bacterial Agents ,Clinical trial ,030104 developmental biology ,030220 oncology & carcinogenesis ,business - Abstract
The use of antibiotics directly correlates with the increase in antimicrobial resistance (AMR). Targeting novel antibiotics to patients with multidrug-resistant (MDR) pathogens should enhance their durability and slow development of resistance. The discovery, development, and clinical adoption of pathogen-targeted antibiotics have been hampered by technical and regulatory challenges. Growing insights into bacterial physiology and mechanisms of resistance, innovative clinical trial designs, streamlined regulatory approval pathways, and availability of rapid bacterial diagnostics are recent developments that can help address those challenges. Pathogen-targeted antibiotics provide an opportunity to treat patients with the right drug at the right time, leading to improved patient outcomes and better antimicrobial stewardship. Patient-centered pricing and reimbursement reform is needed to incentivize innovation.
- Published
- 2021
- Full Text
- View/download PDF